scholarly journals An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema

2014 ◽  
pp. 1565 ◽  
Author(s):  
Sobha Sivaprasad ◽  
Richard Browning ◽  
Carla Starita
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Noncomparative Study ◽  
Open Label ◽  
Pegaptanib Sodium ◽  
One Year

scholarly journals Predictors for 2-year functional and morphological outcomes of a treat and extend regimen with ranibizumab in patients with diabetic macular edema

2021 ◽  
Author(s):  
Helena Giannakaki-Zimmermann ◽  
Alexandra Behrndt ◽  
Laura Hoffmann ◽  
Maria-Magdalena Guichard ◽  
Cengiz Tuerksever ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Loading Dose ◽  
Treatment Frequency ◽  
Treat And Extend ◽  
Free Treatment ◽  
Younger Age ◽  
One Year ◽  
Treat And Extend Regimen

Abstract Purpose: To investigate longer-term functional and morphological outcomes and their predictors in diabetic macular edema (DME) following a treat and extend regimen (TER) without loading dose under ranibizumab. Methods: Patient data were reviewed and analyzed retrospectively over a period of 24 months after initiation of TER. Best-corrected visual acuity (BCVA), treatment frequency as well as quantitative and qualitative Spectral-domain Optical Coherence Tomography parameters were assessed. Results: 118 eyes of 87 patients were included. A mean of 9.742.13 injections in the first and 7.632.29 in the second year were applied. There were significant gains of BCVA and reductions in central retinal thickness from baseline to month 12 and 24 (all p<0.001). Percentage of eyes with an intact inner-/outer segment (IS/OS) junction increased from 15.3% at baseline to 42.1% at month 24 (p<0.001). An intact IS/OS junction at baseline increased the probability of having a dry retina after 12 months by 79.3% (p=0.017) and after 24 months by 88.1% (p=0.040). Less IS/OS disruption at baseline predicted longer maximum recurrence-free treatment intervals at 2 years (r=-0.345, p<0.001) and better BCVA at one year (r=-0.347, p<0.001). Baseline bigger intraretinal cysts were associated with more IS/OS disruption at 24 months (r=0.305, p=0.007). Younger age and lower BCVA at baseline were predictive for a higher BCVA gain at 24 months (p=0.046, p<0.001). Conclusion: Ranibizumab applied in a TER without loading dose in DME significantly improves visual acuity and retinal anatomical structure throughout two years. The evaluated predictors might help to guide routine clinical treatment in DME.

Intravitreal pegaptanib sodium (Macugen) for diabetic macular edema

2008 ◽  
Vol 86 ◽  
pp. 0-0
Author(s):  
G QUERQUES ◽  
AV BUX ◽  
D MARTINELLI ◽  
C IACULLI ◽  
N DELLE NOCI
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Pegaptanib Sodium

Lamellar macular hole following intravitreal pegaptanib sodium (Macugen) injection for diabetic macular edema

2011 ◽  
Vol 31 (6) ◽  
pp. 525-527 ◽  
Author(s):  
Giuseppe Querques ◽  
Anna V. Bux ◽  
Cristiana Iaculli ◽  
Nicola Delle Noci
Keyword(s):  
Macular Edema ◽  
Macular Hole ◽  
Diabetic Macular Edema ◽  
Lamellar Macular Hole ◽  
Pegaptanib Sodium

scholarly journals One-Year Results of Treatment of Diabetic Macular Edema with Aflibercept Using the Treat-and-Extend Dosing Regimen: the VIBIM Study

2020 ◽  
Vol 243 (4) ◽  
pp. 255-262
Author(s):  
Kang Yeun Pak ◽  
Jae Pil Shin ◽  
Hyun Woong Kim ◽  
Min Sagong ◽  
Yu Cheol Kim ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Dosing Regimen ◽  
Treat And Extend ◽  
Results Of Treatment ◽  
One Year

scholarly journals Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Ivan Pochou Lai ◽  
Wei-Lun Huang ◽  
Chung-May Yang ◽  
Chang-Hao Yang ◽  
Tzyy-Chang Ho ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Intravitreal Ranibizumab ◽  
Foveal Thickness ◽  
Corrected Visual Acuity ◽  
Visual Improvement ◽  
Renal Biomarkers ◽  
One Year ◽  
Ranibizumab Treatment

Aims. To investigate the correlations between renal biomarkers and the treatment outcomes of ranibizumab for diabetic macular edema (DME). Methods. This hospital-based study retrospectively enrolled 88 eyes from 67 patients who had received one-year intravitreal ranibizumab treatment for DME. Best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) at baseline and during the follow-up period were recorded. BCVA and OCT characteristics at baseline and their changes after ranibizumab treatment were compared between different proteinuria and estimated glomerular filtration rate (eGFR) groups. Results. Of the 88 eyes studied, those with moderately increased proteinuria had a thicker central subfield foveal thickness (CFT) and a higher proportion of intraretinal cysts than those with no proteinuria (P=0.012 and 0.045, respectively) at baseline. After one year of ranibizumab treatment, the reduction in CFT was greater in patients with severely increased proteinuria than those with normal to mildly increased proteinuria (P=0.030). On the other hand, patients with an eGFR <30 tended to have poorer visual improvements than those with normal eGFR (P=0.044). Conclusions. After ranibizumab treatment for DME, patients with severe proteinuria tended to gain better anatomical improvement, while those with poor eGFR tended to have poorer visual improvement.

Sign in / Sign up

Export Citation Format

Share Document